Elicia Penuel
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Lymphoma Diagnosis and Treatment, HER2/EGFR in Cancer Research, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors(2012)1,105 cited
- → Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(2019)748 cited
- → Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study(2022)401 cited
- → Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)(2019)245 cited
- → Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers(2011)223 cited
- → Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients(2010)161 cited
- → Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study(2019)134 cited
- → Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit(2014)133 cited
- → Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations(2016)133 cited
- → Transformation by v-Src: Ras-MAPK and PI3K-mTOR Mediate Parallel Pathways(1999)130 cited